Komori
Mitani Sangyo (8285) · RiskMaterialised

Impact of Supply Chain Disruptions in the Generic Pharmaceuticals Industry on API Sales

First written in FY2022-Q3. 1 of 1 entries say "Materialised", first in FY2022-Q3. Latest entry: FY2022-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Lower API revenue resulting from supply chain disruptions in the generic pharmaceuticals industryA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3MaterialisedAnnual report

    「API revenue declined due to the impact of adopting the revenue recognition accounting standard, supply chain disruptions in the generic drug industry and a large spot API supply contract in the same period of the previous year.」

    Supply chain disruption in the generic pharmaceuticals industry actually occurred and, together with the reversal of a large project recorded in the same period of the previous year and the adoption of the Accounting Standard for Revenue Recognition, became a factor behind the decline in active pharmaceutical ingredient sales.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Mitani Sangyo's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Impact of Supply Chain Disruptions in the Generic Pharmaceuticals Industry on API Sales | MITANI SANGYO CO.,LTD. (8285) | Komori